| A study of the intracellular routing of cytotoxic ribonucleases YN Wu, SK Saxena, W Ardelt, M Gadina, SM Mikulski, C De Lorenzo, ... Journal of Biological chemistry 270 (29), 17476-17481, 1995 | 137 | 1995 |
| Detection, monitoring, and management of trastuzumab‐induced left ventricular dysfunction: an actual challenge CG Tocchetti, G Ragone, C Coppola, D Rea, G Piscopo, S Scala, ... European journal of heart failure 14 (2), 130-137, 2012 | 113 | 2012 |
| A fully human antitumor immunoRNase selective for ErbB-2-positive carcinomas CD Lorenzo, A Arciello, R Cozzolino, DB Palmer, P Laccetti, R Piccoli, ... Cancer research 64 (14), 4870-4874, 2004 | 112 | 2004 |
| A dimeric mutant of human pancreatic ribonuclease with selective cytotoxicity toward malignant cells R Piccoli, S Di Gaetano, C De Lorenzo, M Grauso, C Monaco, ... Proceedings of the National Academy of Sciences 96 (14), 7768-7773, 1999 | 104 | 1999 |
| Ranolazine protects from doxorubicin‐induced oxidative stress and cardiac dysfunction CG Tocchetti, A Carpi, C Coppola, C Quintavalle, D Rea, M Campesan, ... European journal of heart failure 16 (4), 358-366, 2014 | 94 | 2014 |
| The antitumor action of seminal ribonuclease and its quaternary conformations V Cafaro, C De Lorenzo, R Piccoli, A Bracale, MR Mastronicola, ... FEBS letters 359 (1), 31-34, 1995 | 81 | 1995 |
| A new human antitumor immunoreagent specific for ErbB2 C De Lorenzo, DB Palmer, R Piccoli, MA Ritter, G D’Alessio Clinical cancer research 8 (6), 1710-1719, 2002 | 79 | 2002 |
| Mechanisms of cardiotoxicity associated with ErbB2 inhibitors C Fedele, G Riccio, AE Malara, G D’Alessio, C De Lorenzo Breast cancer research and treatment 134, 595-602, 2012 | 78 | 2012 |
| Cardiotoxic effects, or lack thereof, of anti‐ErbB2 immunoagents G Riccio, G Esposito, E Leoncini, R Contu, G Condorelli, M Chiariello, ... The FASEB Journal 23 (9), 3171-3178, 2009 | 72 | 2009 |
| Pathophysiology of cardiotoxicity from target therapy and angiogenesis inhibitors N Maurea, C Coppola, G Piscopo, F Galletta, G Riccio, E Esposito, ... Journal of Cardiovascular Medicine 17, e19-e26, 2016 | 71 | 2016 |
| Human anti-nucleolin recombinant immunoagent for cancer therapy D Palmieri, T Richmond, C Piovan, T Sheetz, N Zanesi, F Troise, C James, ... Proceedings of the National Academy of Sciences 112 (30), 9418-9423, 2015 | 66 | 2015 |
| The RFG oligomerization domain mediates kinase activation and re-localization of the RET/PTC3 oncoprotein to the plasma membrane C Monaco, R Visconti, MV Barone, GM Pierantoni, MT Berlingieri, ... Oncogene 20 (5), 599-608, 2001 | 66 | 2001 |
| Trastuzumab and target-therapy side effects: Is still valid to differentiate anthracycline Type I from Type II cardiomyopathies? G Riccio, C Coppola, G Piscopo, I Capasso, C Maurea, E Esposito, ... Human vaccines & immunotherapeutics 12 (5), 1124-1131, 2016 | 64 | 2016 |
| From immunotoxins to immunoRNases CD Lorenzo, G D'Alessio Current pharmaceutical biotechnology 9 (3), 210-214, 2008 | 64 | 2008 |
| A human, compact, fully functional anti-ErbB2 antibody as a novel antitumour agent C De Lorenzo, A Tedesco, G Terrazzano, R Cozzolino, P Laccetti, ... British journal of cancer 91 (6), 1200-1204, 2004 | 63 | 2004 |
| Comparison of preclinical cardiotoxic effects of different ErbB2 inhibitors C Fedele, G Riccio, C Coppola, A Barbieri, MG Monti, C Arra, ... Breast cancer research and treatment 133, 511-521, 2012 | 58 | 2012 |
| Intracellular route and mechanism of action of ERB-hRNase, a human anti-ErbB2 anticancer immunoagent C De Lorenzo, C Di Malta, G Calì, F Troise, L Nitsch, G D’Alessio FEBS letters 581 (2), 296-300, 2007 | 52 | 2007 |
| Novel human anti-PD-L1 mAbs inhibit immune-independent tumor cell growth and PD-L1 associated intracellular signalling M Passariello, AM D’Alise, A Esposito, C Vetrei, G Froechlich, E Scarselli, ... Scientific reports 9 (1), 13125, 2019 | 50 | 2019 |
| Cardiotoxicity and pro-inflammatory effects of the immune checkpoint inhibitor Pembrolizumab associated to Trastuzumab V Quagliariello, M Passariello, C Coppola, D Rea, A Barbieri, M Scherillo, ... International Journal of Cardiology 292, 171-179, 2019 | 47 | 2019 |
| Biological properties of a human compact anti-ErbB2 antibody C De Lorenzo, R Cozzolino, A Carpentieri, P Pucci, P Laccetti, ... Carcinogenesis 26 (11), 1890-1895, 2005 | 47 | 2005 |
